NCT07185958Recruiting
Dual Energy CT - a Tool for Delineation of Tumor and Organs at Risk in Radiotherapy
Source: ClinicalTrials.gov · Last updated 29 Oct 2026
Brief summary (registry, in English)
The primary aim of this clinical study, 'Dual Energy CT - a tool for delineation of tumor and organs at risk in radiotherapy' (DART) is to evaluate whether dual-energy CT (DECT) is at least as effective as magnetic resonance imaging (MRI) in delineating both tumors and organs at risk (OARs) in patients referred for radiotherapy (RT). This primary aim will be explored in patient groups where the performance of DECT for RT has been described in the literature (but mostly based on signal-to-noise ratio and/or contrast-to-noise ratio), such as brain metastases (sub-cohort 'DART Brain') and head and neck cancer (sub-cohort 'DART H\&N'). Additionally, DART will explore diagnoses not yet studied in the literature, such as bone metastases (sub-cohort 'DART Bone'). If DECT could be demonstrated to achieve delineations for RT in both tumors and OARs that are equally accurate as those based on MRI, it could offer significant advantages by being faster and more cost-effective, making DECT a valuable alternative to MRI in clinical practice. As a secondary aim, the study will evaluate whether DART offers benefits when added to standard RT imaging for tumor and OAR delineation: (1) For lung cancer patients (sub-cohort 'DART Lung'), where MRI scans are typically not valuable due to tumor motion caused by breathing, 'DART Lung' will assess whether DECT performed in breath-hold provides added value compared to the single-energy CT (SECT) scan conducted during free breathing, as used in current clinical practice. (2) For head and neck cancer patients, 'DART H\&N' will evaluate whether DECT offers added value compared to the positron emission tomography (PET)/CT scan currently used in clinical practice.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 80 (estimated)
- First submitted
- 7 Sept 2025
- Start date
- 14 Oct 2025
- Primary completion date
- 21 Mar 2028
- Lead sponsor
- Aalborg University Hospital
- Diseases
- Head and neck cancer, Lung cancer
- NCT number
- NCT07185958
What you commit to
- Study type: Observational
- Planned participants: 80
- From 14 Oct 2025 to the primary completion date, 21 Mar 2028
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous RT in the same anatomical area now referred for RT
- Previous surgery in the same anatomical area now referred for RT
- If relevant for the protocol scanning regime: Contraindication for MRI (pacemaker, metal, non-MRI, compatible implants etc.)
Other illness
- If relevant for the protocol scanning regime: Allergic to contrast agent
Other
- Pregnancy
- Participation in conflicting protocols
- If relevant for the protocol scanning regime: Contraindication to iodine-based contrast agent for CT (as determined by the physician)
- If relevant for the protocol scanning regime: Contraindication to Gadolinium-based contrast agent for MRI (as determined by the physician)
- Incapable of understanding the patient information
Who the study is looking for
- Age ≥18 years
- ECOG performance status (PS) 0-2
- Assessed to be able to complete the protocol scanning regime
- Referred for RT
- Signed informed consent
- For patients with brain metastasis (cohort A): 1-5 brain metastases referred for ei-ther whole brain or stereotactic RT
- For patients with bone metastasis (cohort B): Metastases in one or more regions of the vertebral column (C1-C7, Th1-12, L1-L5, Os Sacrum), without medullary involve-ment, referred for either palliative or stereotactic RT
- For head and neck cancer patients (cohort C): A PET/CT scan must have been per-formed during the diagnostic evaluation for cancer
- For lung cancer patients (cohort D): Only patients referred for palliative RT with a maximum of 10 fractions
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Aalborg University Hospital Coordinator of this site? Confirm its status | Aalborg | Denmark | Recruiting |
| Copenhagen University Hospital Herlev and Gentofte Coordinator of this site? Confirm its status | Herlev | Denmark | Not yet recruiting |
| Odense University Hospital Coordinator of this site? Confirm its status | Odense | Denmark | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.